Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys

BACKGROUND: Inhibition of activated factor XI (FXIa) is a promising antithrombotic drug target. BMS‐724296 is a selective, reversible, small‐molecule inhibitor of human FXIa (K(i) 0.3 nM). OBJECTIVES: This study assessed effects of BMS‐724296 versus standard‐of‐care oral anticoagulants apixaban (act...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Pancras C., Quan, Mimi L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162232/
https://www.ncbi.nlm.nih.gov/pubmed/34095733
http://dx.doi.org/10.1002/rth2.12524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162232/
https://www.ncbi.nlm.nih.gov/pubmed/34095733
http://dx.doi.org/10.1002/rth2.12524

Ejemplares similares